Expert Insights into Testing and Treatment for HER2-Positive Metastatic Colorectal Cancer (mCRC) : Episode 15
Key Takeaways for Community Oncologists Treating Patients With HER2+ mCRC
The panelists close by emphasizing key takeaways regarding the management of HER2+ colorectal cancer, including early molecular profiling to enable targeted therapy sequencing, assessing HER2 amplification level, and having a strategic plan upfront mapping out potential targeted therapy options rather than just starting chemotherapy.
EP: 1.Overview of Colorectal Cancer (CRC)
EP: 2.Current Treatment Options for CRC
EP: 3.The Role of Biomarker and Molecular Testing in CRC
EP: 4.The Role of HER2 in CRC
EP: 5.Multidisciplinary Care and New Treatment Options in CRC
EP: 6.Case Presentation: A 50-Year-Old Man With Metastatic CRC (mCRC)
EP: 7.Tucatinib in Patients With CRC: Data From MOUNTAINEER-01
EP: 8.Strategies for Adverse Event Management in Patients With CRC Receiving Tucatinib
EP: 9.MOUNAINEER-03: Tucatinib in Combination with Trastuzumab and Chemotherapy in Patients With HER2+ CRC
EP: 10.Case Presentation: A 64-Year-Old Woman With HER2+ mCRC
EP: 11.Trastuzumab Deruxtecan in Patients with HER2+ mCRC: The DESTINY-CRC01 Trial
EP: 12.Managing Interstitial Lung Disease in Patients With HER2+ mCRC Receiving Trastuzumab Deruxtecan
EP: 13.Clinician Insights on the Treatment of Patients With CRC
EP: 14.Future Perspectives and Unmet Needs in HER2+ mCRC Treatment
Now Viewing
EP: 15.Key Takeaways for Community Oncologists Treating Patients With HER2+ mCRC
EP: 16.A Variety of Treatment Options Are Becoming Available in CRC
Recent Videos
Related Content
